-
G288907-10mgS1P1and S1P5agonist.
-
G288907-25mgS1P1and S1P5agonist.
-
G288907-50mgS1P1and S1P5agonist.
-
G288907-5mgS1P1and S1P5agonist.
-
G288522-10mgIntroduction:GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
-
G288522-25mgIntroduction:GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
-
G288522-50mgIntroduction:GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
-
G288522-5mgIntroduction:GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
-
G287297-100mgPotent and selective TRPV4 antagonist: orally active.
-
G287297-10mgPotent and selective TRPV4 antagonist: orally active.
-
G287297-25mgPotent and selective TRPV4 antagonist: orally active.
-
G287297-50mgPotent and selective TRPV4 antagonist: orally active.